J
Jared L. Johnson
Researcher at Cornell University
Publications - 37
Citations - 1975
Jared L. Johnson is an academic researcher from Cornell University. The author has contributed to research in topics: Kinase & Biology. The author has an hindex of 15, co-authored 26 publications receiving 1282 citations. Previous affiliations of Jared L. Johnson include Harvard University & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells
Marc A. Antonyak,Bo Li,Lindsey K. Boroughs,Jared L. Johnson,Joseph E. Druso,Kirsten L. Bryant,David Holowka,Richard A. Cerione +7 more
TL;DR: It is demonstrated that MV shed by two different human cancer cells are capable of conferring onto normal fibroblasts and epithelial cells the transformed characteristics of cancer cells and that this effect requires the transfer of the protein cross-linking enzyme tissue transglutaminase (tTG).
Journal ArticleDOI
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.
Yuling Han,Xiaohua Duan,Xiaohua Duan,Liuliu Yang,Benjamin E. Nilsson-Payant,Pengfei Wang,Fuyu Duan,Xuming Tang,Tomer M. Yaron,Tuo Zhang,Skyler Uhl,Yaron Bram,Chanel Richardson,Jiajun Zhu,Zeping Zhao,David Redmond,Sean Houghton,Duc-Huy T. Nguyen,Dong Xu,Xing Wang,Jose Jessurun,Alain C. Borczuk,Yaoxing Huang,Jared L. Johnson,Yuru Liu,Jenny Xiang,Hui Wang,Lewis C. Cantley,Benjamin R. tenOever,David D. Ho,Fong Cheng Pan,Todd Evans,Huanhuan Joyce Chen,Huanhuan Joyce Chen,Robert E. Schwartz,Shuibing Chen +35 more
TL;DR: This work developed a lung organoid model using human pluripotent stem cells (hPSC-LOs) and performed a high-throughput screen of drugs approved by the FDA and identified entry inhibitors of SARS-CoV-2, including imatinib, mycophenolic acid and quinacrine dihydrochloride.
Journal ArticleDOI
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan,Neil Vasan,Pedram Razavi,Jared L. Johnson,Hong Shao,Hardik Shah,Alesia Antoine,Erik Ladewig,Alexander N. Gorelick,Ting-Yu Lin,Eneda Toska,Guotai Xu,Abiha Kazmi,Matthew T. Chang,Barry S. Taylor,Maura N. Dickler,Maura N. Dickler,Komal Jhaveri,Sarat Chandarlapaty,Raul Rabadan,Ed Reznik,Melissa Smith,Robert Sebra,Frauke Schimmoller,Timothy R. Wilson,Lori Friedman,Lewis C. Cantley,Maurizio Scaltriti,José Baselga +28 more
TL;DR: Preliminary analysis of clinical trial data suggests that breast cancers with double mutations are more responsive to PI3K inhibitors than those with a single mutation, and PIK3CA mutational status could help identify the breast cancer patients most likely to benefit from these drugs.
Journal ArticleDOI
Establishment of a robust single axis of cell polarity by coupling multiple positive feedback loops
Tina Freisinger,Ben Klünder,Jared L. Johnson,Nikola S. Müller,Garwin Pichler,Garwin Pichler,Gisela Beck,Michael Costanzo,Charles Boone,Richard A. Cerione,Erwin Frey,Roland Wedlich-Söldner +11 more
TL;DR: This work shows that in the yeast Saccharomyces cerevisiae a combination of actin- and guanine nucleotide dissociation inhibitor-dependent recycling of the central polarity regulator Cdc42 is needed to establish robust cell polarity at a single site during yeast budding.
Journal ArticleDOI
New Insights into How the Rho Guanine Nucleotide Dissociation Inhibitor Regulates the Interaction of Cdc42 with Membranes
TL;DR: A new model is proposed for how RhoGDI influences the ability of Cdc42 to move between membranes and the cytosol, which highlights the role of the membrane in helping Rho ganine nucleotide dissociation inhibitor to distinguish between the GDP- and GTP-bound forms of CDC42.